Treatment of patients with favorable subsets of unknown primary carcinoma

Carcinoma of an Unknown Primary Site

Volumn , Issue , 2006, Pages 79-91

  Hainsworth, John D ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82555163238     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (43)

1. Wilailak S, Linasmita V, Srivannaboon S. Malignant ascites in female patients: a seven-year review. J Med Assoc Thai 1999; 82:15.
2. Schorge JO, Muto MG, Welch WR, et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germ-line BRCA1 mutations. J Natl Cancer Inst 1998; 90:841.
3. Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer-prone families. Lancet 1982; 2:795.
4. Strnad CM, Grosh WW, Baxter J, et al. Peritoneal carcinomatosis of unknown primary site in women. Ann Intern Med 1989; 111:213-217.
5. Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989; 64:110-115.
6. Ransom DT, Patel SR, Kenney GL, et al. Papillary serous carcinoma of the peritoneum: a review of 33 cases treated with cisplatin-based chemotherapy. Cancer 1990; 66:1091-1094.
7. Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma ofthe peritoneum. Obstet Gynecol 1990; 75:75-79.
8. Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993; 50:347-351.
9. Piver MS, Eltabbakh GH, Hempling RE, et al. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin/doxorubicin/cyclophosphamide or paclitaxel/cisplatin. Gynecol Oncol 1997; 67:141-146.
10. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
11. Vasey PA. Survival and longer-term toxicity of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in ovarian cancer (abstract). Proc Am Soc Clin Oncol 2002; 21:202a.
12. Shah IA, Jayram L, Gani OS, et al. Papillary serous carcinoma of the peritoneum in a man: a case report. Cancer 1998; 82:860-866.
13. Bhatia SK, Saclarides TJ, Witt TR, et al. Hormone receptor studies in axillary metastases from occult breast cancers. Cancer 1987; 59:1170-1172.
14. Block EF, Meyer MA. Positron emission tomography in diagnosis of occult adenocarcinoma of the breast. Am Surg 1998; 64:906-908.
15. Schorn C, Fisher U, Luftner-Nagel S, et al. MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 1999; 9:470-173.
16. Rades D, Kuhnel G, Wildfang I, et al. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001; 12:1605.
17. Nguyen LN, Maor MH, Oswald MJ. Brain metastases as the only manifestation of an undetected primary tumor. Cancer 1998; 83:2181.
18. Salvati M, Cervoni L, Raco A. Single brain metastases from unknown primary malignancies in CT-era. J Neurooncol 1995; 23:75.
19. Motzer RJ, Rodriguez E, Reuter VE, et al. Molecular and cytogenetic studies in the diagnosis of patients with midline carcinomas of unknown primary site. J Clin Oncol 1995; 13:274-282.
20. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316:1435-1440.
21. Fox RM, Woods RL, Tattersall MHN. Undifferentiated carcinoma in young men: the atypical teratoma syndrome. Lancet 1979; 1:1316-1318.
22. Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 1986; 104:547-553.
23. Hainsworth JD, Greco FA. Poorly differentiated carcinoma of unknown primary site. In: Fer MF, Greco FA, Oldham R, eds. Poorly Differentiated Neoplasms and Tumors of Unknown Origin. Orlando, FL: Grune and Stratton, 1986:189-202.
24. Richardson RL, Schoumacher RA, Fer MF, et al. The unrecognized extragona-dal germ cell cancer syndrome. Ann Intern Med 1981; 94:181-186.
25. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10:912-922.
26. Jones AS, Cook JA, Phillips DE, Roland NR. Squamous carcinoma presenting as an enlarged cervical lymph node. Cancer 1993; 72:1756-1761.
27. Carlson LS, Fletcher GH, Oswald MJ. Guidelines for the radiotherapeutic techniques for cervical metastases from an unknown primary. Int J Radiat Oncol Biol Phys 1986; 12:2101-2110.
28. Reddy SP, Marks JE. Metastatic carcinoma in the cervical lymph nodes from an unknown primary site: results of bilateral neck plus mucosal irradiation vs ipsilateral neck irradiation. Int J Radiat Oncol Biol Phys 1997; 37:797-802.
29. Spiro RH, DeRose G, Strong EW. Cervical node metastasis of occult origin. Am J Surg 1983; 146:441-446.
30. Yang ZY, Hu YH, Yan JH, et al. Lymph node metastases in the neck from an unknown primary. Report on 113 patients. Acta Radiol Oncol 1983; 22:17-22.
31. Grau C, Johansen LV, Jakobsen J, et al. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000; 55:121-129.
32. de Braud F, Heilbrun LK, Ahmed K, et al. Metastatic squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an aggressive treatment. Cancer 1989; 64:510-515.
33. Jeremic B, Zivic L, Jevremovic S. Radiotherapy and cisplatin in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. J Chemother 1992; 4:399-402.
34. Guarischi A, Keane TJ, Elhakim T. Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 1987; 59:572-577.
35. Hainsworth JD, Greco FA. Neoplasms ofunknown primary site. In: Kufe DW, Pollock RE, et al. eds. Cancer Medicine. 6th ed. Hamilton: BC Decker, Inc., 2003:2277-2290.
36. Kasimis BS, Wuerker RB, Malefatto JP, Moran EM. Prolonged survival of patients with extrapulmonary small cell carcinoma arising in the neck. Med Pediatr Oncol 1983; 11:27-30.
37. van der Gaast A, Verweij J, Prins E, Splinter TAW. Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas. Cancer 1990; 65:422-424.
38. McKay CE, Hainsworth JD, Burris HA, et al. Treatment of metastatic poorly differentiated neuroendocrine carcinoma with paclitaxel/carboplatin/etoposide (PCE): a Minnie Pearl Cancer Research Network phase II trial (abstract). Proc Am Soc Clin Oncol 2002; 21:158a.
39. Moertel CG, Evols LF, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with etoposide and cisplatin: evidence of major therapeutic activity in anaplastic variants of these neoplasms. Cancer 1991; 68:227-232.
40. Greco FA, Thomas M, Hainsworth JD. Poorly differentiated carcinoma (PDC) or adenocarcinoma (PDA) of unknown primary site: long-term follow-up after cisplatin-based chemotherapy (abstract). Proc Am Soc Clin Oncol 1997; 16:274a.
41. Currow DC, Findlay M, Cox K, Harnett PR. Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. Eur J Cancer 1996; 32A:2357-2359.
42. Lenzi R, Hess KR, Abbruzzese MC, et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown primary carcinoma? J Clin Oncol 1997; 15:2056-2062.
43. Saghatchian M, Fizazi K, Borel C, et al. Carcinoma of unknown primary site: a chemotherapy strategy based on histological differentiation-results of a prospective study. Ann Oncol 2001; 12:535-540.